Company Profile
Inhibrx Stock Price, News & Analysis
- Ticker:
- INBX
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
85.79 USD (+2.26%)
Close
Last updated: August 6, 2026
1.37B USD
Market cap
Why the stock is moving
As of Aug 6, 2026, INBX closed up 2.26% at $85.79. No new same-company headline was identified in the current news window.
Company overview
Business overview
Inhibrx is a biotechnology company focused on engineered biologics and oncology, with a strategy that leans into differentiated protein therapeutics. The company’s story is about building value from precise biologic design.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Inhibrx sits in specialty biotechnology.
Business Model Characteristics
The business depends on clinical data, platform utility, and the ability to create differentiated biologic assets.
Position Within the Biotechnology Landscape
Inhibrx is a platform biologics name whose stock reacts strongly to data and strategic progress.
Future catalysts
For Inhibrx, the near-term story still runs through INBRX-106, PD-L1, and the rest of its current pipeline. Recent commentary puts the focus on Recent Corporate Highlights and Upcoming Milestones INBRX-106 In May 2026, we announced updated interim data from our randomized, first-line Phase 2 portion of the HexAgon study. That leaves the stock tied to whether the next milestone lands on schedule. The partnership angle also matters here, especially around Additionally, in April 2026, we submitted a Biologics License Application (BLA) to the U.S.
Recent news
- 01
- 02
- 03
Inhibrx Reports First Quarter 2026 Financial Results
Source: Inhibrx
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Inhibrx (INBX)?
Inhibrx (INBX) most recently closed at 85.79 USD, a +2.26% move versus the previous session.
What is the market cap of Inhibrx (INBX)?
Inhibrx currently has a market capitalization of 1.37B USD on BioPharmSignal.
What does Inhibrx do?
Inhibrx is a biotechnology company focused on engineered biologics and oncology, with a strategy that leans into differentiated protein therapeutics. The company’s story is about building value from precise biologic design.
On which exchange is INBX stock listed?
Inhibrx (INBX) is associated with NASDAQ, United States, Biopharma.
What is INBRX-106?
For Inhibrx, the near-term story still runs through INBRX-106, PD-L1, and the rest of its current pipeline.
Which conditions is Inhibrx targeting with INBRX-106?
Inhibrx is associated with oncology based on its company overview and current catalyst commentary.
How does Inhibrx describe recent progress with INBRX-106?
For Inhibrx, the near-term story still runs through INBRX-106, PD-L1, and the rest of its current pipeline.
What is PD-L1?
For Inhibrx, the near-term story still runs through INBRX-106, PD-L1, and the rest of its current pipeline.